newsfilter
← Latest News
GlobeNewswire·

Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress

OTLC
  • Oncotelic Therapeutics, Inc. filed its Q1 2026 Form 10-Q with the SEC on May 14, 2026, detailing financial results & a corporate update.
  • The company advanced its deciparticle-based oncology programs through its Sapu Nano joint venture, including work on Sapu003 (IV everolimus) & Sapu006 (IV docetaxel).
  • Oncotelic expanded its AI-enabled biomedical development initiatives by integrating large language models & semantic analysis for biomarker identification & regulatory workflows.
  • Additional strategic activities were completed for the nose-to-brain delivery platform & associated CNS-focused programs.
  • Development of GMP Bio manufacturing infrastructure continued to support clinical-stage & commercial-scale pharmaceutical capabilities.
  • The fair value of Oncotelic's 45% ownership interest in GMP Biotechnology Limited was maintained at approximately $388 million as of March 31, 2026.
  • An independent third-party valuation analysis supported the GMP Bio interest using discounted cash flow & market-based methodologies under ASC 820 guidance.
  • Management concluded that no material events occurred during the quarter requiring adjustment to the previously established fair value or valuation framework.
  • The company maintains rare pediatric designations for DIPG through OT-101 (via GMP Bio), melanoma via CA4P, & AML via OXi 4503.
  • Oncotelic intends to develop its acquired asset AL-101 for Parkinson Disease, erectile dysfunction, female sexual disorder, & hypoactive sexual desire disorder.
  • The press release includes standard forward-looking statement disclaimers regarding future operations, financial position, & regulatory approvals.